mesalamine 66.7 MG/ML Enema [Rowasa]

Verify with CMS →

mesalamine

RxCUI: 206798

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0.3%
Plan Coverage
17
Plans Covering
T3
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for mesalamine 66.7 MG/ML Enema [Rowasa]

Per the CMS 2026 Part D formulary file, mesalamine 66.7 MG/ML Enema [Rowasa] (RxNorm concept RXCUI 206798, generic name mesalamine) appears on 3 distinct formulary files spanning 17 Medicare Part D plan offerings - 0.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.

Real-world access to mesalamine 66.7 MG/ML Enema [Rowasa] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 95,185 Part D beneficiaries filled mesalamine 66.7 MG/ML Enema [Rowasa] in 2023, with total plan-and-beneficiary spending of $271,604,425 and an average per-beneficiary annual cost of $2,853.44. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry mesalamine 66.7 MG/ML Enema [Rowasa] today.

Coverage Details

Formularies covering
3
Plans covering
17
Coverage rate
0.3%
Tier range
Tier 1 – Tier 4
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
95,185
Total spending
$271,604,425
Avg per beneficiary
$2,853.44

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic
15 plans
Tier 4, Non-Preferred

Medicare Advantage Plans (MA-PD) Covering mesalamine 66.7 MG/ML Enema [Rowasa]

17 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) HAMASPIK, INC. T1 No $0 NY
Hamaspik Medicare Select (HMO D-SNP) HAMASPIK, INC. T1 No $34.50 NY
Select Health Medicare Essential (HMO) SELECTHEALTH, INC. T4 No $0 UT
Select Health Medicare Essential (HMO) SELECTHEALTH, INC. T4 No $0 NV
Select Health Medicare Dual (HMO D-SNP) SELECTHEALTH, INC. T4 No $0 UT
Select Health Medicare Essential (HMO) SELECTHEALTH, INC. T4 No $0 UT
Select Health Medicare + Kroger (HMO) SELECTHEALTH, INC. T4 No $0 NV
Select Health Medicare + Kroger (HMO) SELECTHEALTH, INC. T4 No $0 UT
Select Health Medicare Essential (HMO) SELECTHEALTH, INC. T4 No $0 CO
Select Health Medicare Essential (HMO) SELECTHEALTH, INC. T4 No $0 CO
Select Health Medicare + Kroger (HMO) SELECTHEALTH, INC. T4 No $0 CO
Select Health Medicare Flex (HMO) SELECTHEALTH, INC. T4 No $0 CO
Select Health Medicare + Kroger (HMO) SELECTHEALTH, INC. T4 No $0 CO
Select Health Medicare Active (HMO) SELECTHEALTH, INC. T4 No $0 CO
Select Health Medicare Dual (HMO D-SNP) SELECTHEALTH, INC. T4 No $0 NV
Select Health Medicare Wellness (HMO) SELECTHEALTH, INC. T4 No $0 NV
Healthy Mississippi Premier Advantage (HMO-POS) Healthy Mississippi, Inc. T4 No $0 MS

Frequently Asked Questions

Is mesalamine 66.7 MG/ML Enema [Rowasa] covered by Medicare Part D?

Yes, mesalamine 66.7 MG/ML Enema [Rowasa] is covered by 17 Medicare Part D plans (0.3% of all Part D formularies).

What tier is mesalamine 66.7 MG/ML Enema [Rowasa] on Medicare Part D plans?

mesalamine 66.7 MG/ML Enema [Rowasa] averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 4.

Does mesalamine 66.7 MG/ML Enema [Rowasa] require prior authorization?

0% of Part D formularies require prior authorization for mesalamine 66.7 MG/ML Enema [Rowasa]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on mesalamine 66.7 MG/ML Enema [Rowasa]?

In 2023, total Medicare Part D spending on mesalamine 66.7 MG/ML Enema [Rowasa] was $271,604,425, covering 95,185 beneficiaries. The average spend per beneficiary was $2,853.44.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial